![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
20
Polypeptide S.a. Braine-l'alleud Be, based in Switzerland, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Desmopressin, Liquid phase synthesis process , Process F, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2012-037 - Rev 00
This Chemical Type CEP, issued on July 12, 2017, remains in force until May 15, 2023, ensuring its reliability within the pharmaceutical industry.
Substance Number 712 associated with this CEP further emphasizes